Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT02790515
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 60
- Registration Number
- NCT02782546
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 138
- Registration Number
- NCT02766465
- Locations
- 🇺🇸
Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Boston University, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT02728531
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 54
- Registration Number
- NCT02703051
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT02685111
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 4
- Registration Number
- NCT02678533
- Locations
- 🇫🇷
Hôpital necker-Enfants malades, Paris, France
Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure
- Conditions
- Interventions
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- University of Leipzig
- Target Recruit Count
- 176
- Registration Number
- NCT02669680
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪Klinikum der J.W. Goethe- Universität, Frankfurt, Germany
🇩🇪Charité-Campus Virchow-Klinikum, Berlin, Germany
To Assess the Efficacy of Granulocyte Colony Stimulating Factor Versus Standard Medical Therapy in Patients of Decompensated Cirrhosis
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Sir Ganga Ram Hospital
- Target Recruit Count
- 259
- Registration Number
- NCT02642003
- Locations
- 🇮🇳
Department of Gastroenterology & Hepatology, Sir Ganga Ram Hospital, New Delhi, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.